WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413507
CAS#: 36703-88-5 (pranobex)
Description: Inosine pranobex is an alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. Unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly.
Hodoodo Cat#: H413507
Name: Inosine pranobex
CAS#: 36703-88-5 (pranobex)
Chemical Formula: C52H78N10O17
Exact Mass: 0.00
Molecular Weight: 1,115.250
Elemental Analysis: C, 56.00; H, 7.05; N, 12.56; O, 24.39
Related CAS #: 36703-88-5 (pranobex) 141684-35-7 (phosphoramidite) 58-63-9 (free base)
Synonym: Inosine pranobex; NP113; NP-113; NP 113
IUPAC/Chemical Name: 4-acetamidobenzoic acid compound with 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one and 1-(dimethylamino)propan-2-ol (3:1:3)
InChi Key: YLDCUKJMEKGGFI-QCSRICIXSA-N
InChi Code: InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;;;/m1....../s1
SMILES Code: CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(Nc1ccc(C(O)=O)cc1)=O.CC(Nc2ccc(C(O)=O)cc2)=O.CC(Nc3ccc(C(O)=O)cc3)=O.OC[C@H]4O[C@@H](n5c6c(C(NC=N6)=O)nc5)[C@@H]([C@@H]4O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: to be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| To be determined | 0.0 | 0.00 |
The following data is based on the product molecular weight 1,115.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019 Aug;36(8):1878-1905. doi: 10.1007/s12325-019-00995-6. Epub 2019 Jun 5. PMID: 31168764; PMCID: PMC6822865.
2: Tobólska S, Terpiłowska S, Jaroszewski J, Siwicki AK. Genotoxicity and Mutagenicity of Inosine Pranobex. J Vet Res. 2018 Oct 24;62(2):207-213. doi: 10.2478/jvetres-2018-0030. PMID: 30364916; PMCID: PMC6200294.
3: Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648. doi: 10.1186/s12879-016-1965-5. PMID: 27821093; PMCID: PMC5100179.
4: McCarthy MT, Lin D, Soga T, Adam J, O'Callaghan CA. Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression. Eur J Immunol. 2020 Jan;50(1):130-137. doi: 10.1002/eji.201847948. Epub 2019 Sep 12. PMID: 31434164; PMCID: PMC6972573.
5: Beran J, Špajdel M, Katzerová V, Holoušová A, Malyš J, Finger Rousková J, Slíva J. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens. 2020 Dec 16;9(12):1055. doi: 10.3390/pathogens9121055. PMID: 33339426; PMCID: PMC7766462.
6: Glasky AJ, Galli M, Lassus A, Salo O. Inosine pranobex. Lancet. 1985 May 11;1(8437):1103-4. doi: 10.1016/s0140-6736(85)92408-0. PMID: 2582218.
7: De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E. Inosine pranobex in the treatment of HIV infection: a review. Int J Immunopharmacol. 1991;13 Suppl 1:19-27. doi: 10.1016/0192-0561(91)90120-v. PMID: 1726683.
8: Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1986 Nov;32(5):383-424. doi: 10.2165/00003495-198632050-00001. PMID: 2431857.
9: Inosine pranobex and mucocutaneous herpes. Lancet. 1985 Jan 26;1(8422):200-1. PMID: 2578592.
10: You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, Li S, Bai L, Lu J, Wei Z, Chen W, Hao F. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015 Jun;42(6):596-601. doi: 10.1111/1346-8138.12845. Epub 2015 Mar 26. PMID: 25819042.
